ClinicalTrials.gov
ClinicalTrials.gov Menu

Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy (ARB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00511056
Recruitment Status : Completed
First Posted : August 3, 2007
Last Update Posted : July 11, 2011
Sponsor:
Collaborator:
Kirby Institute
Information provided by:
The HIV Netherlands Australia Thailand Research Collaboration

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Study Hypothesis: Do certain risk behaviours impact/predict levels of HIV antiretroviral adherence?

Objectives:

  • To assess risk behavior in HIV-positive individuals receiving highly active antiretroviral therapy.(HAART)
  • To assess levels of adherence in the same subjects at the same time point
  • To determine if there is a correlation between HAART adherence and risk behaviour

Condition or disease
HIV Infections

  Show Detailed Description

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 700 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy
Study Start Date : September 2007
Actual Primary Completion Date : January 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
HIVNAT 006
HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The relationship between sexual risk behavior and adherence to HIV medications and how do these behaviors relate to patient beliefs about HIV transmission. [ Time Frame: 2 Years ]

Biospecimen Retention:   Samples With DNA
Blood samples required to provide Viral Load data and CD4 cell count

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Approximately 500 subjects were surveyed from the HIVNAT 006 long term follow up cohort. A sample size as large as this is likely to yield accurate results as to the true relationship between sexual risk behavior and adherence to HIV medications.
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • HIV seropositive.
  • On continuous HAART for at least 6 months
  • Signed written informed consent
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00511056


Locations
Thailand
HIV-NAT, Thai Red Cross AIDS Research Centre
Bangkok, Thailand, 10330
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Kirby Institute
Investigators
Principal Investigator: Kiat Ruxrungtham, M.D., M.Sc. HIVNAT
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)  This link exits the ClinicalTrials.gov site

Publications of Results:
Honeybrook AL. Adherence and Risk Behaviour in Patients With HIV Recieving antiretroviral therapy. XVII International AIDS Conference 2008. Mexico City, Mexico.

Responsible Party: Dr Kiat Ruxrungtham, The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier: NCT00511056     History of Changes
Other Study ID Numbers: HIV-NAT Amendment II to 006
First Posted: August 3, 2007    Key Record Dates
Last Update Posted: July 11, 2011
Last Verified: July 2011

Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
HIV
Adherence
Compliance
Highly Active Antiretroviral Therapy (HAART)
ARV
 ART
Sexual Risk Behavior
Unsafe
Transmission

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
 Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases